within Pharmacolibrary.Drugs.ATC.M;

model M01BA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.016666666666666666,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01BA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dipyrocetyl is an obscure or possibly obsolete analgesic/antipyretic compound; 'dipyrocetyl and corticosteroids' is a fixed-dose combination drug classified under ATC code M01BA02, indicated historically for inflammatory, rheumatic, and pain-related conditions. It is not widely approved or used in current clinical practice, and available data on its clinical use is extremely limited.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data found in literature or scientific databases for dipyrocetyl, or its combination with corticosteroids, for any population. The below parameters were estimated based on pharmacokinetic properties typical of non-steroidal anti-inflammatory drugs (such as salicylic acid derivatives) for reference adult individuals.</p><h4>References</h4><ol><li><p>Czock, D, et al., &amp; Häussler, U (2005). Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clinical pharmacokinetics</i> 44(1) 61–98. DOI:<a href=\"https://doi.org/10.2165/00003088-200544010-00003\">10.2165/00003088-200544010-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15634032/\">https://pubmed.ncbi.nlm.nih.gov/15634032</a></p></li><li><p>Stout, A, et al., &amp; Standaert, CJ (2019). Systemic Absorption and Side Effects of Locally Injected Glucocorticoids. <i>PM &amp; R : the journal of injury, function, and rehabilitation</i> 11(4) 409–419. DOI:<a href=\"https://doi.org/10.1002/pmrj.12042\">10.1002/pmrj.12042</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30925034/\">https://pubmed.ncbi.nlm.nih.gov/30925034</a></p></li><li><p>Dvořáčková, E, et al., &amp; Hartinger, JM (2024). Bioavailability of Orally Administered Drugs After Bariatric Surgery. <i>Current obesity reports</i> 13(1) 141–153. DOI:<a href=\"https://doi.org/10.1007/s13679-023-00548-7\">10.1007/s13679-023-00548-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38172482/\">https://pubmed.ncbi.nlm.nih.gov/38172482</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01BA02;
